In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: First results from Turkey [2]

International Journal of Antimicrobial Agents

Volumn 23, Issue 6, 2004, Pages 642-643

  Arslan, H ^a   Azap, O K ^a   Ergin, F ^a   Karaman, S O ^a   Oruc E ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HEALTH CENTER; LETTER; MEDICAL ASSESSMENT; MEDICAL INFORMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TURKEY (REPUBLIC);

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TURKEY; VANCOMYCIN RESISTANCE;

EID: 2942607693     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.03.010     Document Type: Letter

References (10)

1. Tally F.P., DeBruin M.F. Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 46:2000;523-526
2. Critchley I.A., Draghi D.C., Sahm D.F., et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother. 51:2003;639-649
3. Petersen P.J., Bradford P.A., Weiss W.J., et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother. 46:2002;2595-2601
4. King A., Philips I. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J Antimicrob Chemother. 48:2001;219-223
5. Jones R.N., Barry A.L. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility test recommendations. Antimicrob Agents Chemother. 45:1987;1919-1922
6. Tongchaun L, Thorne G, Silverman J, et al. Efficacy and breakpoint analysis of daptomycin versus Enterococcus faecalis and Enterococcus faecium renal infection in mice. In: Abstracts of the Thirty-ninth Meeting of the Infectious Diseases Society of America, San Francisco, CA, 2001. Abstract 446. Infectious Diseases Society of America, Alexandra, VA, USA.
7. Richter S.S., Kealey D.E., Murray C.T., et al. The in vitro activity of daptomycin against Staphylococcus and Enterococcus species. J Antimicrob Chemother. 52:2003;123-127
8. Barry A.L., Fuchs P.C., Brown S.D. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers (2001). Antimicrob Agents Chemother. 45:2001;1919-1922
9. Fuchs P.C., Barry A.L., Brown S.D. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media (2001). J Antimicrob Chemother. 48:2001;557-561
10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, sixth ed. Approved Standard M7-A6. NCCLS, PA, USA; 2003.